KROS

SEC source: 0001209191-21-010880 · doc4.xml · nonDerivative · entry 3

Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,384

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.345 to $64.34 inclusive.

SEC source: 0001209191-21-010880 · doc4.xml · nonDerivative · entry 2

Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,844

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.33 to $63.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6).

SEC source: 0001209191-21-010880 · doc4.xml · nonDerivative · entry 1

Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,291

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 12

Knowles Julius · CIK 0001808365 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 453,878

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.59 to $68.05 inclusive.

F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.

SEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 11

Knowles Julius · CIK 0001808365 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 680,668

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.59 to $68.05 inclusive.

F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.

SEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 10

Knowles Julius · CIK 0001808365 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 453,913

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.36 to $67.09 inclusive.

F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.

SEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 9

Knowles Julius · CIK 0001808365 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 680,721

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.36 to $67.09 inclusive.

F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.

SEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 8

Knowles Julius · CIK 0001808365 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 454,119

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.32 to $66.30 inclusive.

F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.

SEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 7

Knowles Julius · CIK 0001808365 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 681,037

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.32 to $66.30 inclusive.

F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.

SEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 6

Knowles Julius · CIK 0001808365 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 455,694

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.32 to $65.25 inclusive.

F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.

SEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 5

Knowles Julius · CIK 0001808365 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 683,455

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.32 to $65.25 inclusive.

F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.

SEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 4

Knowles Julius · CIK 0001808365 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 456,646

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.28 to $64.26 inclusive.

F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.

SEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 3

Knowles Julius · CIK 0001808365 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 684,916

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.28 to $64.26 inclusive.

F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.

SEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 2

Knowles Julius · CIK 0001808365 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 458,172

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.28 to $63.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) (9), (10), (11), (12), (13) and (14).

F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.

SEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 1

Knowles Julius · CIK 0001808365 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 687,251

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.28 to $63.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) (9), (10), (11), (12), (13) and (14).

F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.

SEC source: 0001209191-21-003273 · doc4.xml · derivative · entry 1

Ordonez Claudia · CIK 0001808290 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,250

Underlying: Common Stock · 42,250 shares

Expires 2031-01-09

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on January 7, 2022, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-21-003272 · doc4.xml · derivative · entry 1

Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,250

Underlying: Common Stock · 42,250 shares

Expires 2031-01-09

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on January 7, 2022, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-21-003274 · doc4.xml · derivative · entry 1

Regnante Keith · CIK 0001682068 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,150

Underlying: Common Stock · 49,150 shares

Expires 2031-01-09

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on January 7, 2022, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-21-003271 · doc4.xml · derivative · entry 1

Seehra Jasbir · CIK 0001732369 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,200

Underlying: Common Stock · 127,200 shares

Expires 2031-01-09

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on January 7, 2022, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-20-064654 · doc4.xml · derivative · entry 1

GRAY MARY ANN · CIK 0001261974 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,587

Underlying: Common Stock · 16,587 shares

Expires 2030-12-16

F1 · derivative.exercise_date: One-twelfth (1/12th) of the shares subject to the option shall vest in equal quarterly installments commencing on March 17, 2021, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-20-059404 · doc4.xml · nonDerivative · entry 4

Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner

Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 155,262

F4 · ownership.nature: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds.

F5 · ownership.nature: Each of Management 4 and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-20-059404 · doc4.xml · nonDerivative · entry 3

Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner

Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,228,326

F3 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-20-059404 · doc4.xml · nonDerivative · entry 2

Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner

Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,122,768

F2 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-20-059404 · doc4.xml · nonDerivative · entry 1

Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner

Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,288,151

F1 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-20-059411 · doc4.xml · nonDerivative · entry 4

Nussbaum Ran · CIK 0001609805 · Director · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner

Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 155,262

F4 · ownership.nature: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds.

F5 · ownership.nature: Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-20-059411 · doc4.xml · nonDerivative · entry 3

Nussbaum Ran · CIK 0001609805 · Director · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner

Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,228,326

F3 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-20-059411 · doc4.xml · nonDerivative · entry 2

Nussbaum Ran · CIK 0001609805 · Director · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner

Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,122,768

F2 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-20-059411 · doc4.xml · nonDerivative · entry 1

Nussbaum Ran · CIK 0001609805 · Director · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner

Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,288,151

F1 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-20-059410 · doc4.xml · nonDerivative · entry 4

Kariv Tomer · CIK 0001568077 · Director · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner

Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 155,262

F4 · ownership.nature: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds.

F5 · ownership.nature: Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-20-059410 · doc4.xml · nonDerivative · entry 3

Kariv Tomer · CIK 0001568077 · Director · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner

Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,228,326

F3 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-20-059410 · doc4.xml · nonDerivative · entry 2

Kariv Tomer · CIK 0001568077 · Director · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner

Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,122,768

F2 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-20-059410 · doc4.xml · nonDerivative · entry 1

Kariv Tomer · CIK 0001568077 · Director · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner

Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,288,151

F1 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-20-032991 · doc4.xml · derivative · entry 1

Farzan Nima · CIK 0001808296 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,500

Underlying: Common Stock · 8,500 shares

Expires 2030-05-29

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on each of June 2, 2020, September 2, 2020, December 2, 2020 and March 2, 2021, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-20-024230 · doc4.xml · derivative · entry 5

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VII LLC · CIK 0001760648 · Director

OrbiMed Genesis GP LLC · CIK 0001808744 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 148,922 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F1 · derivative.exercise_date: Each share of Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F1 · derivative.expiration_date: Each share of Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F3 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, OrbiMed GP VII, and OrbiMed Genesis GP LLC ("Genesis GP"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

F4 · ownership.nature: These securities are held of record by OrbiMed Genesis Master Fund, LP ("Genesis"). Genesis GP is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Capital is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of the Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by Genesis.

SEC source: 0001209191-20-024230 · doc4.xml · derivative · entry 4

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VII LLC · CIK 0001760648 · Director

OrbiMed Genesis GP LLC · CIK 0001808744 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 744,612 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F1 · derivative.exercise_date: Each share of Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F1 · derivative.expiration_date: Each share of Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP VII. By virtue of such relationships, OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Capital LLC ("OrbiMed Capital") is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of the Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VII.

F3 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, OrbiMed GP VII, and OrbiMed Genesis GP LLC ("Genesis GP"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001209191-20-024230 · doc4.xml · nonDerivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VII LLC · CIK 0001760648 · Director

OrbiMed Genesis GP LLC · CIK 0001808744 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,119,812

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP VII. By virtue of such relationships, OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Capital LLC ("OrbiMed Capital") is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of the Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VII.

F3 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, OrbiMed GP VII, and OrbiMed Genesis GP LLC ("Genesis GP"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001209191-20-024230 · doc4.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VII LLC · CIK 0001760648 · Director

OrbiMed Genesis GP LLC · CIK 0001808744 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 148,922

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F3 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, OrbiMed GP VII, and OrbiMed Genesis GP LLC ("Genesis GP"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

F4 · ownership.nature: These securities are held of record by OrbiMed Genesis Master Fund, LP ("Genesis"). Genesis GP is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Capital is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of the Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by Genesis.

SEC source: 0001209191-20-024230 · doc4.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VII LLC · CIK 0001760648 · Director

OrbiMed Genesis GP LLC · CIK 0001808744 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 744,612

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP VII. By virtue of such relationships, OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Capital LLC ("OrbiMed Capital") is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of the Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VII.

F3 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, OrbiMed GP VII, and OrbiMed Genesis GP LLC ("Genesis GP"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001209191-20-024228 · doc4.xml · derivative · entry 8

Lazarus Alon · CIK 0001808244 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 167,537 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F2 · ownership.nature: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-024228 · doc4.xml · derivative · entry 7

Lazarus Alon · CIK 0001808244 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 343,270 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F2 · ownership.nature: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-024228 · doc4.xml · derivative · entry 6

Lazarus Alon · CIK 0001808244 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,382,295 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F2 · ownership.nature: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-024228 · doc4.xml · nonDerivative · entry 4

Lazarus Alon · CIK 0001808244 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,013,102

F2 · ownership.nature: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-024228 · doc4.xml · nonDerivative · entry 3

Lazarus Alon · CIK 0001808244 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,893,102

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F2 · ownership.nature: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-024228 · doc4.xml · nonDerivative · entry 2

Lazarus Alon · CIK 0001808244 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,725,565

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F2 · ownership.nature: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-024228 · doc4.xml · nonDerivative · entry 1

Lazarus Alon · CIK 0001808244 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,382,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F2 · ownership.nature: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein.

SEC source: 0001178913-20-001105 · zk2024260.xml · derivative · entry 7

Arkin Bio Ventures Limited Partnership · CIK 0001808348 · 10% owner

Arkin Bio Venture Partners Ltd. · CIK 0001808349 · 10% owner

Arkin Moshe · CIK 0001321178 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 167,537 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F2 · ownership.direct: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd..

SEC source: 0001178913-20-001105 · zk2024260.xml · derivative · entry 6

Arkin Bio Ventures Limited Partnership · CIK 0001808348 · 10% owner

Arkin Bio Venture Partners Ltd. · CIK 0001808349 · 10% owner

Arkin Moshe · CIK 0001321178 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 343,270 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F2 · ownership.direct: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd..

SEC source: 0001178913-20-001105 · zk2024260.xml · derivative · entry 5

Arkin Bio Ventures Limited Partnership · CIK 0001808348 · 10% owner

Arkin Bio Venture Partners Ltd. · CIK 0001808349 · 10% owner

Arkin Moshe · CIK 0001321178 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,382,295 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F2 · ownership.direct: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd..

SEC source: 0001178913-20-001105 · zk2024260.xml · nonDerivative · entry 4

Arkin Bio Ventures Limited Partnership · CIK 0001808348 · 10% owner

Arkin Bio Venture Partners Ltd. · CIK 0001808349 · 10% owner

Arkin Moshe · CIK 0001321178 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,013,102

F2 · ownership.direct: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd..

SEC source: 0001178913-20-001105 · zk2024260.xml · nonDerivative · entry 3

Arkin Bio Ventures Limited Partnership · CIK 0001808348 · 10% owner

Arkin Bio Venture Partners Ltd. · CIK 0001808349 · 10% owner

Arkin Moshe · CIK 0001321178 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,893,102

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.

F2 · ownership.direct: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd..